Fennec Pharma

Fennec Pharmaceuticals focused on the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. Read more

CEO Avatar

CEO

Rostislav Raykov

CEO Approval Rating

51/100

Founded:

06/1996

Status:

PublicIndependent CompanyNASDAQFENC

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Fennec Pharma?

Fennec Pharma Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

Fennec Pharma Acquisitions

No recent acquisitions found related to Fennec Pharma

Fennec Pharma Funding History

Since Fennec Pharma was founded in 06/1996, it has participated in 1 round of funding. In total Fennec Pharma has raised $7.6M. Fennec Pharma's funding round was on Jun 2017 for a total of $7.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Jun 2017
$7.6M
-

Since Fennec Pharma was founded in 06/1996, it has participated in 1 round of funding. In total Fennec Pharma has raised $7.6M. Fennec Pharma's funding round was on Jun 2017 for a total of $7.6M

Fennec Pharma Investments

No recent investments found related to Fennec Pharma

Fennec Pharma News

March 30, 2021BioSpace

Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug App... See more »
March 30, 2021MarketScreener

Corporate Presentation March 2021

(marketscreener.com) March 2021 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement D... See more »
November 16, 2020BioSpace

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully A... See more »
November 5, 2020Seeking Alpha

The Compensation Is What's Missing

November 2, 2020Micro Small Cap

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / November 2, 2020 / The Schall Law Firm, a national shareholder rights ... See more »
October 30, 2020Picante Today

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

LOS ANGELES-(BUSINESS WIRE)-$FENC #classaction-The Law Offices of Frank R. Cruz reminds investors of ... See more »
October 29, 2020Picante Today

Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

NEW YORK-(BUSINESS WIRE)-#Fennec-Bragar Eagel & Squire, P.C., a nationally recognized shareholder rig... See more »

Fennec Pharma Press Releases

June 22, 2020centralcharts

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Com... See more »
April 30, 2020StreetInsider

Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:... See more »
October 2, 2019centralcharts

Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:F... See more »
November 13, 2018GlobeNewswire

Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:F... See more »
September 26, 2018GlobeNewswire

Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City

RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:... See more »
August 13, 2018GlobeNewswire

Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results

RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:F... See more »

Social Media

Fennec Pharma Headquarters

68 Tw Alexander Dr

Research Triangle Park, North Carolina27709

919-636-4530

Driving Directions »

Trending Companies

Fennec Pharma Summary

ABOUT

Overview

Fennec Pharmaceuticals focused on the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. Fennec Pharma was founded in 06/1996. Fennec Pharma's headquarters is located in Research Triangle Park, No...

CEO

Fennec Pharma's CEO, Rostislav Raykov, currently has an approval rating of 51%. Fennec Pharma's primary competitors are

Frequently Asked Questions about Fennec Pharma

  1. When was Fennec Pharma founded?

    Fennec Pharma was founded in 06/1996
  2. Who is Fennec Pharma's CEO?

    Fennec Pharma's CEO is Rostislav Raykov
  3. How much revenue does Fennec Pharma generate?

    Fennec Pharma generates $ < 1M in revenue
  4. How much funding does Fennec Pharma have?

    Fennec Pharma has historically raised $7.6M in funding
  1. Where is Fennec Pharma's headquarters?

    Fennec Pharma's headquarters is in Research Triangle Park North Carolina, USA
  2. How many employees does Fennec Pharma have?

    Fennec Pharma has 3 employees
  3. What sector does Fennec Pharma operate in?

    Fennec Pharma is in Pharmaceuticals